Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease

Pudutha Madhavi; M Vanitha

doi:10.5455/njppp.2021.11.09243202014122020

2024, Vol: 14, Issue: 4

14 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
23 / 12 / 2020

Natl J Physiol Pharm Pharmacol. 2021; 11(4): 397-400

doi: 10.5455/njppp.2021.11.09243202014122020

Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease

Pudutha Madhavi, M Vanitha.

Abstract
Background: A significant public health concern, both preventable and treatable, is chronic pulmonary obstructive disorders (Chronic obstructive pulmonary disease [COPD]). It is one of the primary causes of chronic illness and mortality worldwide. The prominent safety concerns in the use of theophylline need to be addressed.

Aim and Objective: In Grade 12 COPD patients, the efficacy and effectiveness of oral doxofylline should be contrasted with theophylline.

Materials and Methods: Two groups of 25 patients, with one group getting theophylline and the other doxofylline, were randomized to a total of 50 patients in addition to the normal treatment for 12 weeks. Each patient was accompanied by a pulmonary function test (PFT), a COPD assessment test (CAT) evaluation questionnaire, and a drug-related safety review at 6 weeks and 12 weeks for the assessment of efficacy parameters.

Results: At 6 weeks and 12 weeks within their respective classes, theophylline and doxofylline showed substantial increases in PFT and CAT performance. However, there was no noticeable change relative to the two classes. In theophylline group, the amount of adverse drug reactions is larger relative to patients in the doxofylline community. Dyspnea was the most severe harmful effect of all categories.

Conclusion: Doxofylline is also useful in treating Grade 12 COPD (global obstructive lung disease criteria), which has a greater safety profile relative to theophylline.

Key words: Doxofylline; Chronic Pulmonary Obstructive Disease; Chronic Obstructive Pulmonary Disease; Theophylline

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Pudutha Madhavi Articles by M Vanitha
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Madhavi P, Vanitha M. Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. Natl J Physiol Pharm Pharmacol. 2021; 11(4): 397-400. doi:10.5455/njppp.2021.11.09243202014122020

Web Style

Madhavi P, Vanitha M. Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. https://www.njppp.com/?mno=134961 [Access: March 15, 2024]. doi:10.5455/njppp.2021.11.09243202014122020

AMA (American Medical Association) Style

Madhavi P, Vanitha M. Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. Natl J Physiol Pharm Pharmacol. 2021; 11(4): 397-400. doi:10.5455/njppp.2021.11.09243202014122020

Vancouver/ICMJE Style

Madhavi P, Vanitha M. Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. Natl J Physiol Pharm Pharmacol. (2021), [cited March 15, 2024]; 11(4): 397-400. doi:10.5455/njppp.2021.11.09243202014122020

Harvard Style

Madhavi, P. & Vanitha, . M. (2021) Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. Natl J Physiol Pharm Pharmacol, 11 (4), 397-400. doi:10.5455/njppp.2021.11.09243202014122020

Turabian Style

Madhavi, Pudutha, and M Vanitha. 2021. Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. National Journal of Physiology, Pharmacy and Pharmacology, 11 (4), 397-400. doi:10.5455/njppp.2021.11.09243202014122020

Chicago Style

Madhavi, Pudutha, and M Vanitha. "Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 397-400. doi:10.5455/njppp.2021.11.09243202014122020

MLA (The Modern Language Association) Style

Madhavi, Pudutha, and M Vanitha. "Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease." National Journal of Physiology, Pharmacy and Pharmacology 11.4 (2021), 397-400. Print. doi:10.5455/njppp.2021.11.09243202014122020

APA (American Psychological Association) Style

Madhavi, P. & Vanitha, . M. (2021) Comparing the efficacy and safety of theophylline with doxofylline in patients with chronic obstructive pulmonary disease. National Journal of Physiology, Pharmacy and Pharmacology, 11 (4), 397-400. doi:10.5455/njppp.2021.11.09243202014122020

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272